Skip to Content

BioMS Medical Presents at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

EDMONTON, Alberta, Oct. 15, 2007/CNW/ - BioMS Medical Corp. (TSX: MS), a leading  developer in the treatment of multiple sclerosis (MS), today announced that  interim safety observations from MAESTRO-01, the Company's on-going phase III  trial of MBP8298 for the treatment of secondary progressive MS, were reported  in a poster presentation at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague, Czech  Republic. A second poster presentation reported the percentage of patients  screened for the trial that had the target HLA-DR2/DR4 immune response genes.      

ECTRIMS is one of the largest and most prestigious annual MS conferences,  bringing together MS experts and thought leaders from around the world to  discuss the latest MS research findings. The first poster, entitled "Safety observations from administration of  MBP8298 as part of the ongoing phase III MAESTRO-01 secondary progressive MS  clinical trial", showed that MBP8298 administration resulted in no significant  safety concerns measured over the current course of the MAESTRO-01 study.      

The second poster, entitled "Haplotype analysis of Secondary Progressive  Patients participating in the MAESTRO-01 Study", showed that overall, amongst  the 10 countries enrolling patients in the MAESTRO-01 trial, (Canada, United  Kingdom, Finland, Denmark, Sweden, Estonia, Latvia, Spain, Germany and the  Netherlands) 70.38% of the 788 screened patients were observed to have HLA-DR2  and/or HLA-DR4 immune response genes.      

"The first poster presentation demonstrates that the safety profile of  our drug continues to look strong in a large multinational clinical trial  setting," said Kevin Giese, President and CEO of BioMS. "The second poster  reaffirms that MS patients with HLA-DR2/DR4 immune response genes, potentially  account for more than 70% of the overall MS population in Europe and Canada."   

About MBP8298 - Novel Mechanism of Action      
In MS patients, the body's immune system inappropriately attacks the  myelin coating around the nerves in the brain and spinal column, whereas  healthy people are "tolerant" of such normal body components. The proposed  mechanism of action of MBP8298 is, by design, to re-introduce such a state of  "tolerance" to a critical portion of the nerve's Myelin Basic Protein that is  an immunological site of attack in many MS patients. This is accomplished by  the I.V. injection of MBP8298 every six months.      

Phase II and long-term follow-up treatment of MS patients with MBP8298,  recently published in the European Journal of Neurology showed that MBP8298  safely delayed the median time to disease progression for five years in  progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.   

MBP8298 is being developed in three late-stage clinical trials:   

 -  MAESTRO-01: A pivotal phase III trial in Canada and Western Europe evaluating MBP8298 for the treatment of secondary progressive  multiple sclerosis (SPMS). The trial is a randomized, double-blind study and is fully recruited with 611 patients.      

-  MAESTRO-03: A pivotal phase III U.S. trial evaluating MBP8298 for the treatment of SPMS. The trial is a randomized, double-blind study enrolling approximately 510 patients.      

-  MINDSET-01: A phase II trial evaluating MBP8298 for the treatment of relapsing remitting multiple sclerosis (RRMS). The trial is a          randomized, double-blind study and is fully recruited with 218 patients.        

About BioMS Medical Corp.      

BioMS Medical is a biotechnology company engaged in the development and  commercialization of novel therapeutic technologies. BioMS Medical's lead  technology, MBP8298, is for the treatment of multiple sclerosis and is being  evaluated in two pivotal phase III clinical trials for secondary progressive  MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United  States. It additionally is being evaluated for relapsing remitting MS patients  in a Phase II trial in Europe entitled MINDSET-01. For further information  please visit our website at   

This press release may contain forward-looking statements, which reflect  the Company's current expectation regarding future events. These  forward-looking statements involve risks and uncertainties that may cause  actual results, events or developments to be materially different from any  future results, events or developments expressed or implied by such  forward-looking statements. Such factors include, but are not limited to,  changing market conditions, the successful and timely completion of clinical  studies, the establishment of corporate alliances, the impact of competitive  products and pricing, new product development, uncertainties related to the  regulatory approval process and other risks detailed from time to time in the  Company's ongoing quarterly and annual reporting. Certain of the assumptions  made in preparing forward-looking statements include but are not limited to  the following: that MBP8298 will continue to demonstrate a satisfactory safety  profile in ongoing and future clinical trials; and that BioMS Medical Corp.  will complete the respective clinical trials within the timelines communicated  in this release. We undertake no obligation to publicly update or revise any  forward-looking statements, whether as a result of new information, future  events or otherwise.   

For further information: Tony Hesby, Ryan Giese, Corporate  Communications, BioMS Medical Corp., (780) 413-7152, (780) 408-3040 Fax,  E-mail:, Internet:; James Smith,  Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail:   


Posted: October 2007